Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody immunotherapy for leukemia.

J G Jurcic1

  • 1Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA. jurcicj@mskcc.org.

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ab therapy of AML: native anti-CD33 Ab and drug conjugates.

Cytotherapy·2007
Same author

Monoclonal antibody therapy of APL.

Current topics in microbiology and immunology·2007
Same author

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.

Bone marrow transplantation·2003
Same author

Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia.

Blood·2001
Same author

Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2001
Same author

Acute myeloid leukemia with t(5;18)(q35;q21).

Cancer genetics and cytogenetics·2001

Monoclonal antibodies are vital for cancer therapy, showing effectiveness in treating leukemia. Advanced antibody-based therapies offer targeted cancer cell destruction and potential for intensified treatment before transplantation.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Monoclonal antibodies represent a significant advancement in cancer treatment.
  • Genetically engineered antibodies have shown efficacy against leukemia, including minimal residual disease.

Purpose of the Study:

  • To review the role and advancements of antibody-based therapies in leukemia treatment.
  • To highlight novel antibody-targeting strategies for enhanced antileukemic effects.

Main Methods:

  • Review of current literature on monoclonal antibody applications in oncology.
  • Analysis of genetically engineered antibodies, radioimmunotherapy, targeted alpha particle therapy, antibody-drug conjugates, and immunotoxins.

Main Results:

Related Experiment Videos

  • Genetically engineered antibodies demonstrate activity against overt leukemia and minimal residual disease.
  • Radioimmunotherapy and targeted alpha particle therapy offer selective tumor cell kill with minimized normal organ exposure.
  • Antibody-drug conjugates and immunotoxins have achieved complete remissions in leukemia patients.

    • Conclusions:

    • Monoclonal antibodies are a cornerstone of modern leukemia therapy.
    • Innovative antibody-based strategies provide potent and targeted approaches for leukemia management.
    • These therapies hold promise for improving patient outcomes and treatment intensification.